Novel transcript, antisense to SLC51A

ENSG00000309772 denotes a putative long non-coding RNA (lncRNA) described as a "novel transcript, antisense to SLC51A". This annotation means that the transcript is transcribed from the DNA strand opposite to the protein-coding SLC51A gene, but functions of this lncRNA are not established in current biomedical resources. There is no recognized role for this lncRNA in disease, pharmacology, or cellular biology, and it is not an acknowledged therapeutic target. ENSG00000309772 is listed as an lncRNA and not a protein-coding gene; thus, it does not encode a receptor, transporter, enzyme, or other typical drug target class. There are no common aliases or alternative names in standard databases. No biological function, disease association, or pharmacological targeting is currently recognized for this transcript. The annotation "antisense to SLC51A" only describes its genomic orientation and does not imply function, disease relevance, or targetability. As a "novel transcript," information may be incomplete, and its status may change if future research identifies a function or clinical role. Potential source of confusion: The SLC51A gene, which encodes organic solute transporter alpha (OST-alpha), is a functionally characterized bile acid transporter protein and a validated therapeutic target, but ENSG00000309772 is not SLC51A itself; it is an antisense RNA which currently has no known function or target status in pharmacology or therapeutics. Summary: ENSG00000309772, or "novel transcript, antisense to SLC51A," is a genomically annotated, but functionally uncharacterized, lncRNA gene. It is not a therapeutic target, not a receptor, and not known to play any established biological or disease role at this time.